Read about the latest developments in Thioredoxin Systems AB.
EbsArgent targets urinary tract infections, with early indications of efficacy against many species of multidrug-resistant bacteria STOCKHOLM, Oct. 30, 2024 – Thioredoxin Systems AB (TXN
Thioredoxin Systems have become a full member of BEAM Alliance – a vital industry stakeholder for innovative antimicrobial resistance products in Europe! We proudly join
We are incredibly proud to announce that the fundamental aspects of our EbsArgent®️ antimicrobial technology has been awarded with a granted patent by the European
The team is growing, and we are super happy to welcome Carlos Ratia Loncán as our Laboratory Manager! Carlos is a clinical microbiologist and holds
Thioredoxin Systems AB are officially a part of ENABLE-2. Within the frame of ENABLE-2, and with their team and network of world experts in antibiotics
